IRD
Opus Genetics, Inc.
There isn't enough reported data to score IRD yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
IRD Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
IRD's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
IRD PE Valuation
IRD has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
IRD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Growth | |
| -- | |
| Limited | |
| Low |
Analysts expect IRD's losses to grow, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
IRD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.54 | +$0.34 |
| Q2 2026 | -$1.33 | +$0.59 |
| Q1 2026 | -$1.31 | +$0.79 |
| Q4 2025 | -$0.80 | +$1.35 |
| Q3 2025 | -$1.88 | -$0.81 |
| Q2 2025 | -$1.92 | -$1.39 |
| Q1 2025 | -$2.10 | -$1.63 |
| Q4 2024 | -$2.15 | -$1.69 |
IRD is still losing money, but far less than before: $1.54 per share over the past year, against $11.55 at its worst in early 2021.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over IRD on earnings quality, reporting a profit while its opponent remains loss making.
IRD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1M | -63% |
| Q2 2026 | $755K | -74% |
| Q1 2026 | $2.2M | -51% |
| Q4 2025 | $3.9M | -10% |
| Q3 2025 | $3.1M | -20% |
| Q2 2025 | $2.9M | +159% |
| Q1 2025 | $4.4M | +155% |
| Q4 2024 | $4.3M | +154% |
IRD's revenue has slid since its 2022 peak: $1M last quarter, down 63% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1693% | -1423 points |
| Q2 2026 | -2183% | -1874 points |
| Q1 2026 | -666% | -439 points |
| Q4 2025 | -296% | +588 points |
| Q3 2025 | -270% | -63 points |
| Q2 2025 | -309% | +440 points |
| Q1 2025 | -227% | +223 points |
| Q4 2024 | -884% | -563 points |
IRD's operating margin was −1693% last quarter, down 1423 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over IRD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over IRD on profitability, with a higher operating margin.
IRD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$12M | -$1.7M |
| Q1 2026 | -$12.7M | -$3.7M |
| Q4 2025 | -$9.8M | -$2.4M |
| Q3 2025 | -$6.2M | -$1M |
| Q2 2025 | -$10.3M | -$3M |
| Q1 2025 | -$9M | -$3.3M |
| Q4 2024 | -$7.4M | -264% |
| Q3 2024 | -$5.1M | -$2.1M |
IRD has burned cash in almost every quarter: −$41M over the past year, against −$32M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over IRD on cash generation, producing positive trailing cash flow while its opponent burns cash.
IRD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -8.6% | -9.5M shares |
| 1 year | +44% | +31.2M shares |
| 3 years | +386% | +80.9M shares |
| 5 years | +832% | +90.9M shares |
| Available history | +10187% | +101M shares |
IRD has 102M diluted shares, up 44% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over IRD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
IRD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -2.3x | Net Cash |
IRD has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
IRD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.5 | Neutral |
| Stochastic | 20.4 | Neutral |
IRD's weekly RSI is 50 (neutral) and its Stochastic is 20 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
IRD PE vs Healthcare Sector
| Metric | IRD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
IRD has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
IRD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.15 | 2.2% below |
| 20 week MA | $4.12 | 1.5% below |
| 50 week MA | $3.91 | 3.8% above |
| 100 week MA | $2.58 | 57% above |
| 200 week MA | $2.68 | 51% above |
IRD has slipped below its 8- and 20-week averages, though it's still 51% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over IRD on trend strength, trading above more of its moving averages.
IRD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.08 | $5.49 | -32% |
| 2021 | $5.49 | $3.81 | -31% |
| 2022 | $3.81 | $2.51 | -34% |
| 2023 | $2.51 | $3.01 | +20% |
| 2024 | $3.01 | $1.18 | -61% |
| 2025 | $1.18 | $2.02 | +71% |
| 2026 YTD | $2.02 | $4.06 | +101% |
IRD has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.